FDA Rejects Approval of Kangfang Biotech's Cancer Drug Ivonescimab
The U.S. Food and Drug Administration (FDA) has rejected the approval of the cancer drug Ivonescimab submitted by Summit Therapeutics, which was originally developed by China's Kangfang Biotech. Summit Therapeutics is headquartered in Miami, and on Monday, Kangfang Biotech's stock, listed in Hong Kong, fell by 24%. In 2022, Kangfang Biotech licensed the drug to Summit, with a total transaction value of up to $5 billion. In September of this year, AstraZeneca invested $2 billion in Summit and acquired an 11% stake. The FDA stated that the drug has not established sufficient evidence of efficacy and has not shown a significant improvement in patient survival rates. Summit's co-CEO Robert Duggan expressed disappointment regarding this decision. The approval of Ivonescimab by the FDA was one of the first applications for treatment regimens targeting multiple cancers. Analysts pointed out that this rejection was not unexpected and should not affect the applications for the company's other drugs. Among the clinical trial data submitted to the FDA, 62% of the participants were Asian, while 38% were Western, and investment bank TD Cowen raised concerns that the patient composition might influence the FDA's decision. Kangfang Biotech is regarded as a leading company in China's biotechnology industry and secured a significant presentation slot at the American Society of Clinical Oncology (ASCO) annual meeting in June of this year.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027

Johnson & Johnson Delivered 'Immaculate' Prostate Cancer Data at ESMO. Here's Why Investors Should Care

Real-Life Theranos: New Blood Testing Startup Claims to Predict Health Risks

Novartis Raises Sales Forecast for Three Major Drugs to $18 Billion, Expected Annual Growth Rate of 5% by 2031

Sellas Life Sciences Cancer Vaccine Extends Patient Survival in Blood Cancer Clinical Trial

Moderna's Cancer Vaccine Shows Promise, Stock Valuation Raises Concerns

NVIDIA Launches Nemotron for Science to Accelerate Scientific Discoveries with Intelligent Agents

Former Employee Sues Ethereum Foundation, Claims Retaliatory Dismissal After Protesting 'Seppuku' Clause

BRT.Fit Founder Calls for Incorporating Exercise Habits into Cancer Prevention

Nixo sues Ethereum Foundation, Vitalik Buterin over 'suicide pledge' claim

U.S. Senate Rejects Long-Term Regulation Legislation for the Cryptocurrency Industry

Proteomic clocks link accelerated aging to higher risk of death and disease

Aging is not linear: cells go through coordinated stages of deterioration

Trump and Islamophobia: The Chorus That No Longer Mobilizes Votes

Jennifer Tilly Earns Up to $10 Million a Year from The Simpsons Without Ever Participating: Her Story

Crypto: Netflix Series on FTX Sparks Reactions from CZ and Vitalik Buterin

Solana upgrades to mainnet 1.0 as Foundation takes majority CoinGecko stake

IOSCO Warns of 'Quantum Delay' and Assesses Readiness for Quantum Threat

Deribit outage hit Bitcoin hedgers on Coinbase

Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?

J.P. Morgan Says Tesla's Robotaxi Fleet Could Match Waymo's Miles by Late 2027 With 18,000 Cars. The Number That Matters Is How Much Each Car Earns.

What's Going on with The Trade Desk Stock? 3 Reasons Investors Are Losing Confidence.

Bitcoin’s next big threat could come from two oil tankers in the Middle East

Bitcoin: Network Power Rises, Profits Disappear

Parliament: Pre-sale of Babak Zanjani's cryptocurrency is illegal; DotOne lacks exchange license

Altria Yields 5.8% and Has Raised Its Dividend 61 Times in 57 Years. Here's Exactly How Much $5,000 Invested Pays Each Year.

Not Lucid. Not Ford. The EV Stock Most Likely to Catch Every Refunded Cybertruck Buyer.

Bitcoin’s $60,000 breakdown puts December Fed decision under the spotlight

The Stock Market Is Doing Something for Only the 5th Time This Century, and History Says It's Obvious What Comes Next for Stocks









